Author: admin

  • Royal United Hospitals Bath in stroke treatment drug trials

    Royal United Hospitals Bath in stroke treatment drug trials

    Researchers are looking for volunteers to take part in a study to see if two medications could help prevent recurrent strokes and their negative impact on cognitive function.

    Royal United Hospitals Bath (RUH Bath) has launched a recruitment drive…

    Continue Reading

  • Nutritionist warns if you don’t want to suffer from breast cancer do these 5 things: ‘If you don’t get enough oxygen…’

    Nutritionist warns if you don’t want to suffer from breast cancer do these 5 things: ‘If you don’t get enough oxygen…’

    Breast cancer is one of the leading causes of cancer death for women in many countries, and the most common cancer found in women globally. In 2022, the World Health Organisation (WHO) estimated that 670,000 women died from breast cancer…

    Continue Reading

  • Jersey ADHD conference prompts ‘the start of real change’

    Jersey ADHD conference prompts ‘the start of real change’

    Chris CraddockBBC Jersey communities reporter

    BBC A conference setting with attendees seated at round tables facing a stage. On the stage, a speaker stands near a podium with a banner that reads “ADHD Jersey” and a large screen displaying the title “The Many Faces of ADHD.” The room has modern lighting and wood-paneled walls.BBC

    Speakers focused on what improvements were needed to make the island more neuroinclusive

    Organisers of a two-day conference on attention deficit hyperactivity disorder (ADHD) said they hoped it would…

    Continue Reading

  • Vietnam flood death toll rises to 35: disaster agency – Business Recorder

    1. Vietnam flood death toll rises to 35: disaster agency  Business Recorder
    2. At least 35 dead as record floods devastate central Vietnam  TRT World
    3. Vietnam flood death toll rises to 13, with 11 others missing  Dunya News
    4. Hope as tourists return to…

    Continue Reading

  • Aisin (TSE:7259) Margin Recovery to 3.4% Reinforces Case for Turnaround, Eases Profitability Doubts

    Aisin (TSE:7259) Margin Recovery to 3.4% Reinforces Case for Turnaround, Eases Profitability Doubts

    Aisin (TSE:7259) reported a net profit margin of 3.4%, a significant jump from last year’s 0.6%. The company also posted earnings growth of 479.2% over the past year, well above its five-year average of 1.4%. Looking ahead, earnings are forecast to grow at 6.7% per year as the company continues its streak of profitability and margin improvement. Investors are now weighing positive earnings momentum, constructive valuation signals, and minor questions around dividend sustainability as they assess the results.

    See our full analysis for Aisin.

    Next, we will see how these headline numbers measure up against the market’s consensus narratives, highlighting where expectations meet results and where surprises emerge.

    Curious how numbers become stories that shape markets? Explore Community Narratives

    TSE:7259 Earnings & Revenue History as at Nov 2025
    • Net profit margin reached 3.4%, reversing course from last year’s low of 0.6% and signaling that the shift into profitability now looks more durable over a multi-year horizon.

    • The prevailing market view sees this margin restoration as heavily supporting the case that Aisin is adapting to sector challenges by building quality recurring profits, rather than just chasing short-term gains.

      • Ongoing annual earnings growth at 1.4% over the past five years now gets a boost with a sharp 479.2% jump this year, implying a reset of stable returns at higher levels.

      • Analysts will closely watch if the projected 6.7% annual earnings growth materializes, especially as the company’s profitability profile continues to improve year over year.

    • Aisin’s share price stands at 2,774.5, notably under the DCF fair value of 5,082.25 and also trades at a price-to-earnings ratio of 12.1x, which is below the peer average of 15.8x but slightly above the industry average of 11.6x.

    • The data-driven analysis points to a balanced view that recognizes the valuation discount as a meaningful positive for value-seeking investors, while keeping sight of possible reasons for the gap.

      • The P/E discount suggests that the company is comparatively undervalued versus peers, reinforcing structural strengths such as sustained profitability.

      • However, with a minor flag about dividend sustainability and the share price below DCF fair value, investors remain cautious not to overlook long-run capital returns in pursuit of immediate bargains.

    • The only material risk spotlighted is the minor question over whether Aisin’s current dividend can be maintained, especially as the company pivots to driving up profit margins and earnings growth.

    • What is surprising is that despite the margin and profitability improvements, there is still skepticism about payouts keeping pace going forward.

      • Steady revenue growth forecast at 2.3% per year and improving profits should support healthy cash flow, but a more cautious stance remains around capital allocation.

      • This risk does not undermine the growth story, but adds a layer of due diligence for investors prioritizing income reliability alongside capital appreciation.

    Continue Reading

  • Stories you may have missed

    Stories you may have missed

    BBC A huge model of Mars hanging from the roof of Truro CathedralBBC

    The sculpture was created by artist Luke Jerram

    A 7m (21ft) wide sculpture of Mars on display at Truro Cathedral has been providing lots of school half-term fun.

    The artwork called Mars: War and Peace was created by Luke Jerram and follows his…

    Continue Reading

  • Ocean predators may need twice the prey when food quality drops

    Ocean predators may need twice the prey when food quality drops

    In 2014, something strange happened to the fish off the West Coast of the United States. The ocean warmed fast and stayed that way for a long time. This wasn’t a small change – it was a massive heat wave, and it seriously messed with marine…

    Continue Reading

  • With 88% ownership of the shares, Tristel plc (LON:TSTL) is heavily dominated by institutional owners

    With 88% ownership of the shares, Tristel plc (LON:TSTL) is heavily dominated by institutional owners

    • Institutions’ substantial holdings in Tristel implies that they have significant influence over the company’s share price

    • The top 9 shareholders own 52% of the company

    • Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business

    We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

    To get a sense of who is truly in control of Tristel plc (LON:TSTL), it is important to understand the ownership structure of the business. We can see that institutions own the lion’s share in the company with 88% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

    Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.

    In the chart below, we zoom in on the different ownership groups of Tristel.

    View our latest analysis for Tristel

    AIM:TSTL Ownership Breakdown November 2nd 2025

    Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

    We can see that Tristel does have institutional investors; and they hold a good portion of the company’s stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there’s always a risk that they are in a ‘crowded trade’. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Tristel’s historic earnings and revenue below, but keep in mind there’s always more to the story.

    earnings-and-revenue-growth
    AIM:TSTL Earnings and Revenue Growth November 2nd 2025

    Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. We note that hedge funds don’t have a meaningful investment in Tristel. Liontrust Asset Management PLC is currently the largest shareholder, with 9.9% of shares outstanding. Rathbones Investment Management Limited is the second largest shareholder owning 8.4% of common stock, and Raymond James Wealth Management Limited holds about 7.7% of the company stock.

    Continue Reading

  • Weight loss jab warning: fraudsters’ fake products ‘could cause real harm’ | Scams

    Weight loss jab warning: fraudsters’ fake products ‘could cause real harm’ | Scams

    You have heard and read so much about people using weight loss injections to get slim, you feel it is time to give it a go in the run-up to the festive season. The problem is cost.

    But it seems there are other options rather than getting a prescription from a doctor and going to the pharmacy. A text message arrives giving a link to a site with much cheaper medication – and with no need to go through official channels. And you saw a similar ad on social media the other day, so you decide to go for it.

    The problem is these ads are almost certainly scams. In the best-case scenario, you will be sent nothing and lose whatever money you paid. In the worst, you receive a fake version, with unknown ingredients that could lead to severe health problems.

    The popularity of legitimate weight loss medications has led to a rise in fake goods hitting the market and scams set up to simply take people’s money.

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has warned against buying these illegal weight loss medicines without a prescription from beauty salons, fake pharmacy websites or via social media, saying they could contain “toxins and other ingredients that could cause real harm”.

    New figures from the high street bank Santander show a sharp rise in the number of customers who have been affected by the fraud. The bank says the amount of money lost to scams involving weight loss injections, pens, tablets and fat-dissolving products between July and September this year, was more than double the total sum stolen in the previous three months. The average scam costs victims £120, it says.

    “Fraudsters are actively exploiting people’s insecurities and health concerns, with these scams soaring in recent months,” says Michelle Pilsworth, the bank’s head of fraud.

    What it looks like

    Most take place on messaging apps and social media. On socials, an account may mimic the brand that you are looking for, but there will typically be subtle differences in spelling or logos.

    The messages or posts will often use urgency-laden phrases such as “limited-time offer”, “exclusive deal” or “free giveaway”.

    As the price of some legitimate weight loss jabs, such as Mounjaro, has increased recently, the fraudsters will price their “product” lower.

    “Buying from unverified sellers online can come at a serious financial, health-related and emotional cost,” says Pilsworth.

    What to do

    As with all scams, the old adage applies: if it appears too good to be true, then it probably is.

    The MHRA has warned people to be extremely cautious when buying medicines online. They should only be obtained from a registered pharmacy using a prescription issued by a healthcare professional, it says. If sourced elsewhere, they may pose serious risks to health.

    Criminals can go to great lengths to make their site or social media page look as authentic as possible. If they claim to be an online pharmacy based in Great Britain, you can check the website of the General Pharmaceutical Council (GPhC) to ensure this is properly registered.

    Continue Reading

  • Smart feature management to extend pacemaker battery life • healthcare-in-europe.com

    Smart feature management to extend pacemaker battery life • healthcare-in-europe.com

    Together, the patient and the doctor can discuss which functions are necessary, and which are ‘nice to have’, as well as what cost to the battery there is for each option

    Klaus Witte

    Dr Klaus Witte, Senior Lecturer and Consultant Cardiologist…

    Continue Reading